Cabio Biotech Wuhan Co Ltd Asset Resilience Ratio
Cabio Biotech Wuhan Co Ltd asset resilience ratio. Cabio Biotech Wuhan Co Ltd (688089) has an Asset Resilience Ratio of 3.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cabio Biotech Wuhan Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cabio Biotech Wuhan Co Ltd (2020–2024)
Asset resilience ratio of Cabio Biotech Wuhan Co Ltd from 2020 to 2024. This chart shows how Cabio Biotech Wuhan Co Ltd's Asset Resilience Ratio has changed over time. Read 688089 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cabio Biotech Wuhan Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Cabio Biotech Wuhan Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥65.70 Million | 3.6% |
| Total Liquid Assets | CN¥65.70 Million | 3.60% |
Asset Resilience Insights
- Limited Liquidity: Cabio Biotech Wuhan Co Ltd maintains only 3.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cabio Biotech Wuhan Co Ltd Industry Peers by Asset Resilience Ratio
Compare Cabio Biotech Wuhan Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Cabio Biotech Wuhan Co Ltd Asset Resilience Ratio by Year (2020–2024)
Cabio Biotech Wuhan Co Ltd asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for Cabio Biotech Wuhan Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CN¥31.39K ≈ $4.59K |
CN¥1.69 Billion ≈ $246.83 Million |
0.00pp |
| 2023-12-31 | 0.00% | CN¥31.04K ≈ $4.54K |
CN¥1.61 Billion ≈ $235.81 Million |
-2.03pp |
| 2022-12-31 | 2.04% | CN¥32.80 Million ≈ $4.80 Million |
CN¥1.61 Billion ≈ $235.71 Million |
+1.24pp |
| 2021-12-31 | 0.79% | CN¥11.50 Million ≈ $1.68 Million |
CN¥1.45 Billion ≈ $211.96 Million |
-0.18pp |
| 2020-12-31 | 0.98% | CN¥13.52 Million ≈ $1.98 Million |
CN¥1.38 Billion ≈ $202.35 Million |
-- |
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.